On January 23, 2017, the Department of Health and Human Services (HHS) revised Mandatory Guidelines for Federal Workplace Drug Testing Programs effective October 1, 2017.
If your organization complies with the HHS standards currently, whether by policy, support of federal testing programs or voluntary drug testing state laws, you must now comply with new panel standards effective October 1, 2017.
If your organization identifies specific drug panels in your current policy, updated policy language should be seriously considered, also covering adulterated specimens, oral fluid testing in shy bladder situations, observed collection safeguards, the emerging legal issues of anti-discrimination protection for medical marijuana card holders in certain states, and pre-duty disclosure of impairing effect drugs and substances for those working in safety-sensitive occupations.
Key points in the guidelines:
If you are not already a client, contact us for a free demo!
HHS revised guidelines in its 51 page Federal Register release:
This information is provided by EBI for general educational purposes. It should not be deemed as legal guidance or advice. Always consult with legal counsel for specific advice on applicable laws, industry regulation, and compliance matters.
Jennifer Gladstone is a news anchor and journalist with more than 20 years of experience in front of the camera. She's worked in several markets, large and small, and has performed nearly every task needed in a newsroom. As EBI’s Screening News Editor, she keeps EBI’s customers and blog subscribers up to date on the latest screening news and legislative alerts affecting companies of all sizes.